Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous menstrual blood stem cell intra-ovarian injection for poor ovarian response
IRCT20180619040147N4Phase 3Completed
- Sponsor
- ACECR
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous menstrual blood stem cells in poor ovarian response (POR) and female infertility (2 arms), sponsored by ACECR. Primary endpoints: Number of antral follicles, Anti-Mullerian hormone level and 8 more. Started Jun 2020; status: completed.
02
Drugs
autologous menstrual blood stem cells
03
Conditions
poor ovarian response (POR)female infertility
Beyond the preview
Go deeper on IRCT20180619040147N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180619040147N4.